Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice

Journal of Drugs in Dermatology

Volumn 13, Issue 3, 2014, Pages 269-273

  Bettencourt, Miriam S ^a,b  

^a Bettencourt Skin Center   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; PREDNISONE; TACROLIMUS; 3-INGENYL ANGELATE; DERMATOLOGICAL AGENT; DITERPENE; GEL;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CRYOSURGERY; DISEASE CLEARANCE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; RETROSPECTIVE STUDY; SKIN CANCER; SKIN DISEASE; SWELLING; VERY ELDERLY; GEL; INTRADERMAL DRUG ADMINISTRATION; KERATOSIS, ACTINIC; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CRYOSURGERY; DERMATOLOGIC AGENTS; DITERPENES; FEMALE; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896380859     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J. Dermatolog. Treat. 2006;17:162-166. (Pubitemid 44147835)
2. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int. J. Dermatol. 2004;43:638-642. (Pubitemid 39276288)
3. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br. J. Dermatol. 2002;146:94-100. (Pubitemid 34158414)
4. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335-339. (Pubitemid 41757441)
5. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad. Dermatol. 2010;62:582-590.
6. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 2012;366:1010-1019.
7. Picato (ingenol mebutate) gel 0.015%, 0.05% [package insert]. Parsippany, NJ: LEO Pharma Inc; 2012.
8. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J. Drugs Dermatol. 2008;7:669-673.
9. Jorizzo JL, Markowitz O, Lebwohl MG, et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J. Drugs Dermatol. 2010;9:1101-1108.
10. Berman B., Marmur E., Melgaard A. Three-day topical treatment with ingenol mebutate gel 0.015% for actinic keratoses on the face and scalp: analysis of data pooled from two trials. Poster no. P5623. Presented at the annual meeting of the American Academy of Dermatology, March 16-20, 2012, San Diego, CA.
11. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol. 1998;38:77-80. (Pubitemid 28100469)
12. Jeffes EW, III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin. Dermatol. 2000;1:167-179.